中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2014年
32期
7-8
,共2页
氯沙坦%糖尿病%转化生长因子-β1﹙TGF-β1﹚%Smad7
氯沙坦%糖尿病%轉化生長因子-β1﹙TGF-β1﹚%Smad7
록사탄%당뇨병%전화생장인자-β1﹙TGF-β1﹚%Smad7
Losartan%Diabetes mellitus%Transforming growth factor beta 1 (TGF-β1)%Smad7
目的：探讨血管紧张素Ⅱ﹙AngⅡ﹚受体阻滞剂氯沙坦对糖尿病大鼠胰岛组织中转化生长因子﹙TGF﹚-β1及smad7表达的影响。方法选取90只健康成年Wistar大鼠作为本组实验的观察对象,随机将其分为健康组﹑糖尿病组及糖尿病氯沙坦组各30只,健康组采用普通饲料喂养方式,糖尿病组与糖尿病氯沙坦组采用高脂﹑高热量饲料喂养方式,喂养8周后糖尿病组和糖尿病氯沙坦组分别注射链脲佐菌素﹙STZ﹚诱导糖尿病大鼠模型,造模成功后,给予糖尿病氯沙坦组大鼠氯沙坦30 mg/﹙kg?d﹚灌胃治疗,并于8周后对比各组大鼠的体质量﹑血糖﹑血胰岛素及TGF-β1及Smad7蛋白的表达变化。结果①糖尿病组与糖尿病氯沙坦组的血糖水平分别为﹙19.3±2.7﹚mmol/L与﹙13.1±1.6﹚mmol/L,均明显高于健康组,血胰岛素及体质量均低于健康组,差异有统计学意义﹙P<0.05﹚。②糖尿病对照组与糖尿病氯沙坦组胰岛组织中的TGF-β1含量分别为﹙0.41±0.11﹚与﹙0.15±0.09﹚mmol/L,均有所增加；Smad7蛋白含量分别为﹙0.23±0.08﹚与﹙0.36±0.11﹚,均有所降低,糖尿病氯沙坦组的各项指标均有明显改善,优于糖尿病对照组,差异有统计学意义﹙P<0.05﹚。结论AngⅡ受体阻滞剂氯沙坦可以降低胰腺组织中TGF-β1蛋白的表达,减少TGF-β1及Smad7蛋白在尿液中的排泄,抑制糖尿病大鼠胰岛组织纤维化,从而起到保护肾脏的作用。
目的：探討血管緊張素Ⅱ﹙AngⅡ﹚受體阻滯劑氯沙坦對糖尿病大鼠胰島組織中轉化生長因子﹙TGF﹚-β1及smad7錶達的影響。方法選取90隻健康成年Wistar大鼠作為本組實驗的觀察對象,隨機將其分為健康組﹑糖尿病組及糖尿病氯沙坦組各30隻,健康組採用普通飼料餵養方式,糖尿病組與糖尿病氯沙坦組採用高脂﹑高熱量飼料餵養方式,餵養8週後糖尿病組和糖尿病氯沙坦組分彆註射鏈脲佐菌素﹙STZ﹚誘導糖尿病大鼠模型,造模成功後,給予糖尿病氯沙坦組大鼠氯沙坦30 mg/﹙kg?d﹚灌胃治療,併于8週後對比各組大鼠的體質量﹑血糖﹑血胰島素及TGF-β1及Smad7蛋白的錶達變化。結果①糖尿病組與糖尿病氯沙坦組的血糖水平分彆為﹙19.3±2.7﹚mmol/L與﹙13.1±1.6﹚mmol/L,均明顯高于健康組,血胰島素及體質量均低于健康組,差異有統計學意義﹙P<0.05﹚。②糖尿病對照組與糖尿病氯沙坦組胰島組織中的TGF-β1含量分彆為﹙0.41±0.11﹚與﹙0.15±0.09﹚mmol/L,均有所增加；Smad7蛋白含量分彆為﹙0.23±0.08﹚與﹙0.36±0.11﹚,均有所降低,糖尿病氯沙坦組的各項指標均有明顯改善,優于糖尿病對照組,差異有統計學意義﹙P<0.05﹚。結論AngⅡ受體阻滯劑氯沙坦可以降低胰腺組織中TGF-β1蛋白的錶達,減少TGF-β1及Smad7蛋白在尿液中的排洩,抑製糖尿病大鼠胰島組織纖維化,從而起到保護腎髒的作用。
목적：탐토혈관긴장소Ⅱ﹙AngⅡ﹚수체조체제록사탄대당뇨병대서이도조직중전화생장인자﹙TGF﹚-β1급smad7표체적영향。방법선취90지건강성년Wistar대서작위본조실험적관찰대상,수궤장기분위건강조﹑당뇨병조급당뇨병록사탄조각30지,건강조채용보통사료위양방식,당뇨병조여당뇨병록사탄조채용고지﹑고열량사료위양방식,위양8주후당뇨병조화당뇨병록사탄조분별주사련뇨좌균소﹙STZ﹚유도당뇨병대서모형,조모성공후,급여당뇨병록사탄조대서록사탄30 mg/﹙kg?d﹚관위치료,병우8주후대비각조대서적체질량﹑혈당﹑혈이도소급TGF-β1급Smad7단백적표체변화。결과①당뇨병조여당뇨병록사탄조적혈당수평분별위﹙19.3±2.7﹚mmol/L여﹙13.1±1.6﹚mmol/L,균명현고우건강조,혈이도소급체질량균저우건강조,차이유통계학의의﹙P<0.05﹚。②당뇨병대조조여당뇨병록사탄조이도조직중적TGF-β1함량분별위﹙0.41±0.11﹚여﹙0.15±0.09﹚mmol/L,균유소증가；Smad7단백함량분별위﹙0.23±0.08﹚여﹙0.36±0.11﹚,균유소강저,당뇨병록사탄조적각항지표균유명현개선,우우당뇨병대조조,차이유통계학의의﹙P<0.05﹚。결론AngⅡ수체조체제록사탄가이강저이선조직중TGF-β1단백적표체,감소TGF-β1급Smad7단백재뇨액중적배설,억제당뇨병대서이도조직섬유화,종이기도보호신장적작용。
Objective To study the effects of angiotensin II (Ang II) receptor blocker losartan on the expression of transforming growth factor beta 1 (TGF-β1) and Smad7 protein in the pancreatic tissue of diabetic rats. Methods 90 healthy adult Wistar rats were selected as the object of observation of this experiment, and they were randomly divided into healthy group, diabetic group and diabetes losartan group with 30 rats in each. The healthy group was treated with normal feed, the diabetic group and diabetes losartan group were treated with the high fat and calorie feed. 8 weeks after feeding, the diabetic group and diabetes losartan group were injected with streptozotocin (STZ) for induction of diabetic rats model. After the success of modeling, the rats in the diabetes losartan group were given intragastric administration of losartan 30 mg/kg/d. And 8 weeks later, the changes in body weight, blood glucose, blood insulin and expression of TGF-β1 and Smad7 protein were compared between the groups. Results (1) The blood glucose of the diabetic group and the diabetes losartan group was (19.3±2.7) mmol/L, (13.1±1.6) mmol/L, respectively, significantly higher than that of the healthy group, respectively, while the blood insulin and body weight were lower than those of the healthy group, P<0.05. (2) The TGF-beta 1 content in the diabetic control group and the diabetes losartan group was (0.41±0.11) mmol/L, (0.15 ±0.09) mmol/L, respectively, all increased; Smad7 protein content was (0.23 ±0.08) and (0.36 ±0.11), respectively, all de_creased, the indicators in the diabetes losartan group improved significantly, better than the diabetic control group with statistical significance, P<0.05. Conclusion Ang II receptor blocker losartan can reduce the expression of TGF-beta 1 protein in pancreatic tissue, decrease the excretion of TGF-beta 1 and Smad7 protein in the urine, inhibit the fibrosis of pancreatic islet tissue of dia_betic rats, thus it can protect the kidney.
